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Summary
. Data regarding the urea reduction ratio (URR) were
available for analysis from 63 renal centres in the
UK.
. Fifty centres provided URR data on more than 90%
of prevalent haemodialysis (HD) patients.
. The proportion of patients in the UK who met the
Renal Association clinical practice guideline for
URR (.65%) increased from 77.7% in 2002 to
88.1% in 2015.
. There was persistent variation observed between
centres, 20 centres attaining the RA clinical practice
guideline in.90% of patients and 36 centres attain-
ing the guideline in 70–90% of patients.
. Patients over the age of 70 years achieved a higher
median URR (76.0%) compared to younger patients
(,70 years, URR 75.0%).
. The overall proportion of prevalent HD patients
with a URR .65% has continued to improve over
time.
. Whilst the majority of UK patients achieved the
target URR there was wide variation between
centres in the percentage of patients achieving the
current guideline target.
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Introduction
Following the National Co-operative Dialysis Study
(NCDS) [1], dialyser urea clearance has been used to assess
the amount of dialysis treatment delivered to patients
with chronic kidney disease. The most widely accepted
measures of dialysis urea clearance are the dimensionless
Kt/V urea, the ratio between the product of dialyser urea
clearance (K) and dialysis session duration (t) divided by
the volume of urea distribution in the body (V) [1] and
the urea reduction ratio (URR), the percentage fall in
serum urea (URR) following a haemodialysis treatment.
URR does not consider ultraﬁltration or the size of the
patient, and although Kt/V urea takes both into account,
both URR and Kt/V urea can over-estimate dialyser urea
clearance due to the rebound in serum urea concentration
at the end of dialysis, particularly when higher blood pump
speeds are used, and if blood sampling does follow
approved protocols [2]. Whilst Kt/V provides a better
estimate of urea clearance, it requires additional data
items not routinely reported by most UK kidney dialysis
centres [3, 4]. As such, the UK Renal Registry (UKRR)
has historically presented analyses based on URR rather
than Kt/V urea for comparative audit of haemodialysis
adequacy as these data are more readily available.
Although observational studies have reported that
urea dialyser clearance inﬂuences patient survival [5, 6],
the prospective multicentre Haemodialysis (HEMO)
study failed to demonstrate that a higher haemodialysis
Kt/V urea target improved survival [7]. Despite debates
as to the toxicity of urea, or whether urea clearance
equates to the clearance of other azotaemic toxins [8],
errors in estimating urea volume of distribution [9], or
the effect of energy expenditure [10, 11], clinical guide-
lines base dialysis dosing on dialyser urea clearance
[12–14]. Despite the limited number of randomised
prospective trials, there is marked uniformity for the rec-
ommendations of the various national and international
guideline committees for the minimum amount of dialy-
ser urea clearance, although there are some differences in
the methodology advised [12–14]. Table 6.1 lists the
current Renal Association (RA) audit measures relevant
to haemodialysis patients and whether the audit measure
is currently reported in the UKRR annual report [12].
The main objective of this chapter is to examine the
extent to which patients with chronic kidney disease
treated with haemodialysis (HD) in the UK, received
the minimum dose of HD as determined by URR,
recommended in the current UK RA clinical practice
guidelines [12].
The RA clinical practice guidelines for HD dose apply
speciﬁcally to patients undergoing thrice weekly HD. In
these patients, it is recommended that blood for biochemi-
cal measurement (including pre-dialysis urea for URR)
should be taken before the mid-week dialysis session [12].
Methods
Seventy renal centres in the UK submitted data electronically
to the UKRR on a quarterly basis. Cambridge renal centre (Adden-
brooke’s) was unable to submit 2015 data at patient level prior to
the UKRR closing date for data submission, but provided summary
numbers of patients starting RRT by treatment modality. This
centre is therefore excluded from most analyses in this chapter.
Table 6.1. Summary of recommended Renal Association audit measures relevant to haemodialysis adequacy
Haemodialysis adequacy RA audit measures
Included in UKRR
annual report? Reason for non-inclusion
The proportion of patients in the main renal unit and its satellite units
who are on twice weekly haemodialysis
No Varying levels of reporting
between centres
Cumulative frequency curves of urea reduction ratio measured using a
standard method of post-dialysis sampling




The proportion of patient non-attendances for haemodialysis sessions
and the proportion of dialysis sessions shortened at the patient’s request
No Data not available
The proportion of thrice weekly haemodialysis sessions which have
prescribed treatment times less than 4 hours
Yes
The proportion of hospital (main and satellite unit) and home
haemodialysis patients who are prescribed more frequent than thrice
weekly haemodialysis
Partly Not for home
haemodialysis patients
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The majority of these centres have satellite units but for the pur-
poses of this study the data from the renal centres and their associ-
ated satellite units were amalgamated. Data from two groups of
patients were analysed. Firstly, analysis was undertaken using
data from the prevalent adult HD patient population as of the
30th September 2015. For this analysis, data for URR were taken
from the 3rd quarter of 2015 unless that data point was missing
in which case data from the 2nd quarter were taken. The prevalent
population only included patients receiving HD who were alive on
30th September 2015. Data from those patients who had died
before that date have not been included in the analysis. The second
analysis involved adult incident patients who had commenced
treatment with HD during 2014. For these patients, analysis was
undertaken using the last recorded URR in the quarter in which
the patient had started dialysis. The incident HD patient cohort
was followed up for one year and the last recorded URR in the
quarter after one year follow-up was used for this analysis.
Data from patients known to be receiving more or less than
thrice weekly HD were omitted from the analysis for both the inci-
dent and prevalent population. Patients who had missing data for
the number of dialysis sessions per week, were assumed to be
dialysing thrice weekly. However, because not all centres report
frequency of HD, it is possible that data from a small number of
patients receiving HD at a different frequency were included in
the analyses. Home HD patients were excluded from the analysis.
Analyses of the data from both groups of patients included the
calculation of the median URR and of the proportion of patients
who had achieved the RA guideline (as outlined below) in each
of the renal centres, the UK countries as well as for the UK as a
whole. The median URR and proportion of patients who achieved
the RA guideline were also calculated separately for males and
females. The number of dialysis sessions per week and the time
per dialysis session is shown by renal centre.
All patients with data were included in the statistical analyses at
a national level, although centres with fewer than 20 patients, or
providing less than 50% data completeness were excluded from
the comparison between centres. The number preceding the centre
name in each ﬁgure indicates the percentage of missing data for
that centre.
The UK RA clinical practice guidelines [12] in operation at the
time these data were collected, were as follows:
HD should take place at least three times per week in
nearly all patients. Reduction of dialysis frequency to
twice per week because of insufﬁcient dialysis facilities is
unacceptable.
Every patient receiving thrice weekly HD should have
consistently:
. either URR >65%
. or equilibrated Kt/V (eKt/V) of >1.2 (or single pool Kt/V
of >1.3) calculated from pre- and post-dialysis urea values,
duration of dialysis and weight loss during dialysis.
To achieve a URR above 65% or eKt/V above 1.2 consist-
ently in the vast majority of the HD population clinicians
should aim for a minimum target URR of 70% or minimum
eKt/V of 1.4 in individual patients.
The duration of thrice weekly HD in adult patients with
minimal residual renal function should not be reduced
below 4 hours without careful consideration.
Patients receiving HD twice weekly for reasons of geogra-
phy should receive a higher sessional dose of HD. If this
cannot be achieved, then it should be recognised that there
is a compromise between the practicalities of HD and the
patient’s long-term health.
Measurement of the ‘dose’ or ‘adequacy’ of HD should be
performed monthly in all hospital HD patients and may be
performed less frequently in home HD patients. All dialysis
units should collect and report this data to their regional
network and the UKRR.
Post-dialysis blood samples should be collected either by
the slow-ﬂow method, the simpliﬁed stop-ﬂow method, or
the stop dialysate ﬂow method. The method used should
remain consistent within renal units and should be reported
to the Registry.
The RA clinical practice guidelines for HD dose apply speciﬁ-
cally to patients undergoing thrice weekly HD. In these patients,
it is recommended that blood for biochemical measurement
(including pre-dialysis urea for URR) should be taken before the
mid-week dialysis session [12].
Results
Data completeness
Sixty three of the 71 UK renal centres submitted HD
dose (URR) data to the UKRR (table 6.2). Data were
available for 72.0% (N = 14,866) of the total prevalent
population (N = 20,653) treated with HD who met the
inclusion criteria for these analyses.
Fifty centres reported URR data on more than 90%
of their patients. Seven centres reported URR data on
less than 50% of prevalent patients (Brighton, Ipswich,
Manchester Royal Inﬁrmary, Newcastle, Reading,
Shrewsbury and Sunderland). URR data were not
received from eight centres (Cambridge, Carshalton,
London St Bartholomew’s, London Kings, London
Royal Free, London St Georges, Liverpool Aintree and
Liverpool Royal Inﬁrmary).
Several centres had a reduction in the completeness of
URR data submitted to the UKRR in 2015 compared with
2014, whereas others increased reporting, with an average
change of 0.1% (range −99.1 to 99.4%). These changes
may have occurred due to changes in computerised
data bases and data extraction, or by centres moving to
on-line Kt/V, or total Kt/V urea including residual
renal urea clearance rather than URR as the preferred
measure of haemodialysis dose.
Twelve centres, including all ﬁve centres in Wales, did
not provide data on frequency of dialysis sessions, and 50
centres provided data on .90% of patients (table 6.3).
Twelve centres did not provide data on dialysis session
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times, and 45 centres provided data on .90% of patients
(table 6.4).
Of the total incident patient population (N = 4,591)
who started HD during 2014 and meeting the inclusion
criteria for URR analyses, 43% (N = 1,976) had URR
data available during the ﬁrst quarter of treatment (data
not shown). Ten centres did not provide data for the
ﬁrst quarter of treatment, and 42 centres provided data
on .90% of incident patients during the ﬁrst year.
Achieved URR
The median URR for prevalent HD patients was 75%,
but ranged between centres from 70–83% (ﬁgure 6.1a).
There was evidence that the median URR for female







B Heart 348 99.1 Sheff 471 94.9
B QEH 890 97.3 Shrew 162 1.9
Basldn 133 97.7 Stevng 398 98.5
Bradfd 199 99.0 Sthend 90 100.0
Brightn 352 11.1 Stoke 265 91.3
Bristol 445 100.0 Sund 193 1.6
Camb Truro 115 85.2
Carlis 74 98.7 Wirral 157 99.4
Carsh 718 0.0 Wolve 273 93.0
Chelms 114 94.7 York 117 100.0
Colchr 111 92.8
Covnt 320 99.7 N Ireland
Derby 190 96.8 Antrim 107 100.0
Donc 148 98.0 Belfast 154 98.7
Dorset 249 86.4 Newry 74 85.1
Dudley 143 96.5 Ulster 86 100.0
Exeter 360 100.0 West NI 87 98.9
Glouc 208 100.0
Hull 317 99.4 Scotland
Ipswi 115 0.9 Abrdn 185 100.0
Kent 360 98.3 Airdrie 176 100.0
L Barts 918 0.0 D & Gall 46 97.8
L Guys 535 98.9 Dundee 159 100.0
L Kings 509 0.0 Edinb 241 99.6
L Rfree 652 0.0 Glasgw 512 99.4
L St.G 303 0.0 Inverns 64 98.4
L West 1,332 88.7 Klmarnk 123 100.0
Leeds 424 100.0 Krkcldy 139 99.3
Leic 783 99.0
Liv Ain 141 0.0 Wales
Liv Roy 274 0.0 Bangor 67 100.0
M RI 429 2.6 Cardff 428 100.0
Middlbr 303 100.0 Clwyd 70 100.0
Newc 255 15.3 Swanse 304 99.7
Norwch 277 98.2 Wrexm 97 100.0
Nottm 316 91.1
Oxford 389 98.2 England 17,534 67.1
Plymth 120 95.0 N Ireland 508 97.2
Ports 491 99.0 Scotland 1,645 99.6
Prestn 485 80.0 Wales 966 99.9
Redng 275 10.6 UK 20,653 72.0
Salford 288 69.8
Blank cells denote no data returned by the centre
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Table 6.3. Number of dialysis sessions for prevalent patients on HD by centre, on 30/9/2015
Percentage
Percentage
Centre N completeness ,3 sessions 3 sessions .3 sessions
England
B Heart 389 77.9 11.6 86.5 2.0
B QEH 890 0.0
Basldn 141 97.2 0.0 94.2 5.8
Bradfd 210 99.5 5.3 94.7 0.0
Brightn 355 99.4 0.6 99.2 0.3
Bristol 465 100.0 3.2 95.7 1.1
Camb
Carlis 75 93.3 1.4 98.6 0.0
Carsh 726 99.6 0.6 98.9 0.6
Chelms 131 97.7 11.7 86.7 1.6
Colchr 111 100.0 0.0 100.0 0.0
Covnt 320 1.9
Derby 190 52.6 0.0 100.0 0.0
Donc 149 94.6 0.7 99.3 0.0
Dorset 260 99.6 3.9 95.8 0.4
Dudley 146 98.6 2.1 97.9 0.0
Exeter 383 99.7 4.2 94.0 1.8
Glouc 208 0.0
Hull 317 1.0
Ipswi 123 100.0 6.5 93.5 0.0
Kent 371 98.4 2.2 97.0 0.8
L Barts 918 0.0
L Guys 576 97.9 4.1 92.7 3.2
L Kings 509 100.0 0.0 100.0 0.0
L Rfree 652 0.0
L St.G 305 92.5 0.7 99.3 0.0
L West 1,342 55.4 0.9 98.7 0.4
Leeds 456 99.8 6.4 93.0 0.7
Leic 792 98.5 1.2 98.8 0.0
Liv Ain 147 97.3 0.7 95.8 3.5
Liv Roy 318 98.4 0.3 85.9 13.7
M RI 431 23.9
Middlbr 304 21.7
Newc 261 100.0 1.1 97.7 1.1
Norwch 284 99.7 1.4 97.5 1.1
Nottm 335 100.0 0.3 94.3 5.4
Oxford 389 99.2 0.0 100.0 0.0
Plymth 120 0.0
Ports 545 98.2 6.4 89.9 3.7
Prestn 485 0.0
Redng 277 98.2 0.4 99.3 0.4
Salford 347 99.7 1.7 82.9 15.3
Sheff 486 99.2 3.1 96.9 0.0
Shrew 177 100.0 5.1 91.5 3.4
Stevng 428 99.5 4.7 93.0 2.3
Sthend 105 100.0 14.3 85.7 0.0
Stoke 278 98.2 1.5 95.2 3.3
Sund 205 98.5 0.0 94.1 5.9
Truro 135 92.6 13.6 84.0 2.4
Wirral 169 96.5 0.6 92.6 6.7
Wolve 273 8.8
York 129 99.2 0.8 90.6 8.6
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HD patients at 78% (centre range 72.0–86.5%)
(ﬁgure 6.1b) was signiﬁcantly greater than that of male
HD patients, with a median URR at 74% (centre range
68–80%) (ﬁgure 6.1c).
The median sessional URR was lower for patients aged
,70 years (median 75%) compared to older patients
(570 years, median 76%), and there was evidence that
this difference was signiﬁcant. Similarly, the median ses-
sional URR was lower for both genders in the younger age
group (,70 years) compared to the older age group
(570 years of age): median URR of 77% for females
,70 years of age compared to a median URR of 78%
for female patients aged 570 years. Similarly, for male
patients aged ,70 years of age the median URR of
73.0% was lower than for male patients aged 570 years
(median URR 74.3%).
The current UK RA clinical guideline target is to
achieve a minimum sessional URR of 65%, and this
was achieved in 88.1% of HD prevalent patients (centre
range 73.5–97.3%) (ﬁgure 6.2). Again, more female
patients achieved this minimum target (92.3%, centre
range 83.9–100.0%) compared to male patients (85.5%,
centre range 63.4–96.5%) and there was evidence that
this difference was signiﬁcant.
Changes in URR over time
From 2002 there was an initial progressive increase in
the percentage of patients achieving the current RA
clinical practice guidelines (URR .65%) until 2011,
after which there has been a plateau (ﬁgure 6.3). Simi-
larly, the median URR in UK haemodialysis patients




Centre N completeness ,3 sessions 3 sessions .3 sessions
N Ireland
Antrim 108 98.2 0.0 99.1 0.9
Belfast 162 100.0 0.6 95.1 4.3
Newry 79 100.0 6.3 93.7 0.0
Ulster 90 100.0 2.2 95.6 2.2
West NI 101 100.0 2.0 86.1 11.9
Scotland
Abrdn 196 96.9 1.1 94.2 4.7
Airdrie 177 94.9 0.6 99.4 0.0
D & Gall 47 100.0 0.0 97.9 2.1
Dundee 162 98.2 0.0 98.1 1.9
Edinb 248 98.8 0.8 97.1 2.0
Glasgw 516 94.2 0.4 99.2 0.4
Inverns 70 87.1 0.0 90.2 9.8
Klmarnk 123 97.6 0.0 100.0 0.0







England 18,138 68.9 2.7 95.2 2.2
N Ireland 540 99.6 1.9 94.1 4.1
Scotland 1,681 95.8 0.6 97.8 1.7
Wales 966 0.0
UK 21,325 68.7 2.4 95.4 2.2
Blank cells denote no data returned by the centre
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Table 6.4. Time per dialysis session for prevalent patients on HD by centre, on 30/9/2015
Percentage
Percentage per dialysis session
Centre N completeness ,4 hours 4–5 hours .5 hours
England
B Heart 348 70.4 11.8 87.8 0.4
B QEH 890 0.0
Basldn 133 97.0 38.0 61.2 0.8
Bradfd 199 98.0 25.1 74.9 0.0
Brightn 352 99.4 6.6 93.4 0.0
Bristol 445 100.0 20.0 80.0 0.0
Camb
Carlis 74 93.2 11.6 88.4 0.0
Carsh 718 96.9 10.2 89.5 0.3
Chelms 114 97.4 40.5 59.5 0.0
Colchr 111 100.0 2.7 97.3 0.0
Covnt 320 3.8
Derby 190 52.6 2.0 98.0 0.0
Donc 148 94.6 28.6 71.4 0.0
Dorset 249 100.0 10.8 89.2 0.0
Dudley 143 98.6 9.9 90.1 0.0
Exeter 360 100.0 48.9 51.1 0.0
Glouc 208 0.0
Hull 317 2.2
Ipswi 115 93.0 3.7 96.3 0.0
Kent 360 100.0 57.8 41.9 0.3
L Barts 918 0.0
L Guys 535 90.8 19.5 80.0 0.4
L Kings 509 100.0 47.3 52.7 0.0
L Rfree 652 0.0
L St.G 303 80.5 3.3 96.7 0.0
L West 1,332 55.8 16.4 82.1 1.5
Leeds 424 100.0 23.6 76.2 0.2
Leic 783 81.6 11.3 86.5 2.2
Liv Ain 141 98.6 27.3 72.7 0.0
Liv Roy 274 99.6 9.5 90.1 0.4
M RI 429 23.5
Middlbr 303 99.7 38.1 61.9 0.0
Newc 255 100.0 10.2 87.8 2.0
Norwch 277 99.6 60.1 39.9 0.0
Nottm 316 100.0 9.2 90.8 0.0




Redng 275 96.4 13.2 86.8 0.0
Salford 288 97.2 22.9 77.1 0.0
Sheff 471 83.2 88.0 11.5 0.5
Shrew 162 99.4 52.2 47.2 0.6
Stevng 398 100.0 67.6 32.4 0.0
Sthend 90 100.0 45.6 54.4 0.0
Stoke 265 100.0 13.2 86.8 0.0
Sund 193 81.9 17.7 82.3 0.0
Truro 115 96.5 60.4 39.6 0.0
Wirral 157 100.0 24.8 74.5 0.6
Wolve 273 8.8
York 117 98.3 7.0 93.0 0.0
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Table 6.4. Continued
Percentage
Percentage per dialysis session
Centre N completeness ,4 hours 4–5 hours .5 hours
N Ireland
Antrim 107 98.1 13.3 86.7 0.0
Belfast 154 100.0 16.2 83.8 0.0
Newry 74 100.0 44.6 55.4 0.0
Ulster 86 100.0 17.4 82.6 0.0
West NI 87 100.0 57.5 42.5 0.0
Scotland
Abrdn 185 96.2 2.8 94.9 2.2
Airdrie 176 96.6 14.7 83.5 1.8
D & Gall 46 89.1 9.8 90.2 0.0
Dundee 159 98.1 13.5 86.5 0.0
Edinb 241 98.8 34.0 66.0 0.0
Glasgw 512 95.7 5.7 90.4 3.9
Inverns 64 85.9 23.6 76.4 0.0
Klmarnk 123 97.6 0.8 93.3 5.8







England 17,534 64.7 26.7 72.9 0.4
N Ireland 508 99.6 27.1 72.9 0.0
Scotland 1,645 96.0 13.8 84.0 2.2
Wales 966 0.0
UK 20,653 65.0 25.2 74.2 0.6















































































































































































































































































































Fig. 6.1a. Median URR achieved in prevalent patients on HD by centre, 30/9/2015

























































































































































































































































































































































































































































































































































































































































































































































































































































































































UCL N = 14,866
% with URR >65%
LCL
UK mean
Fig. 6.2. Percentage of prevalent patients on HD with URR .65% by centre, 30/9/2015
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with no substantial change in the median sessional URR
from 2011.
Variation of achieved URR with time on dialysis
The proportion of patients who attained the UK RA
clinical guideline for URR was greater for those who
had been treated by haemodialysis for two years or longer
compared to those who had been dialysing for ,6
months (ﬁgure 6.4). For all strata of dialysis vintage,
there has been an improvement in the proportion of
patients receiving the sessional target dose of haemodia-
lysis over the last 13 years, with the greatest increase in
those dialysing for ,6 months where the proportion of
patients achieving the URR target increased from 54%
to 75% from 2002 to 2015.
Changes in URR for incident patients
The median sessional URR during the ﬁrst quarter
after starting haemodialysis treatment in the UK was
68.0% (centre range 57.0–75.0%) (ﬁgure 6.5a) for inci-
dent HD patients in 2014. At the end of one year
follow-up, the median URR had signiﬁcantly increased
to 74.0% (centre range 69.0–80.0%) (ﬁgure 6.5b).
There was evidence that the median sessional URR
during the ﬁrst three months after starting haemodialysis
was signiﬁcantly lower for patients aged ,70 years
(median URR 67.0%) compared to patients older than
570 years (median URR 69.0%). Similarly, at the end
of the ﬁrst year of haemodialysis the median sessional
URR was again lower for patients aged ,70 years
(median URR 73.0%) vs 570 years of age (median
URR 75.0%).
Haemodialysis session duration for prevalent HD
patients
For those centres which returned data, the vast
majority of prevalent patients (74.2%) dialysed between
4–5 hours, with 25.2% dialysing ,4 hours per session,
and only 0.6% dialysing for more than 5 hours
(table 6.4). Median URR was similar for patients dialysing
longer (54 hours) vs shorter dialysis sessions (,4
hours).
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URR >65% and 95% Cl
Median URR
and quartiles
Fig. 6.3. Change in the percentage of
prevalent patients on HD with URR .65%
and the median URR between 2002 and 2015





























Fig. 6.4. Percentage of prevalent patients
on HD achieving URR .65% by time on
RRT between 2002 and 2015
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Haemodialysis session frequency for prevalent
HD patients
Dialysis frequency data was available for 68.7% of
patients (table 6.3). Although 95.4% of all prevalent
haemodialysis patients dialysed thrice weekly, 2.4%
dialysed less frequently and 2.2% more than thrice
weekly, there were marked differences in centre practices.
Centres reported dialysing between 0–14.3% of patients
twice weekly or less, and between 0–15.3% more than
thrice weekly. Four centres reported dialysing .10% of
patients less than thrice weekly and three centres more
often than thrice weekly. There was little evidence that
sessional URR differed with dialysis frequency (median
URR 74.0% for prevalent HD patients dialysising ,3
times per week versus a median URR of 75.0% for
patients dialysing 53 times per week.
Discussion
The original NCDS trial studying different low ﬂux
dialyser urea clearance targets, recruited a much younger
and less comorbid cohort of patients than currently
dialysing in UK centres [1]. That trial showed no differ-
ence in one year mortality, but more patients dropped out
of the trial with lower sessional dialyser urea clearances
possibly affecting the results [1]. As such, patient well-




















































































































































































































































































































































































UK median N = 2,224
Fig. 6.5b. Median URR one year after starting RRT for incident patients who started HD in 2014
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dialyser urea clearance target, but it remains unclear as to
whether higher dialyser urea clearance targets increase
patient survival [3, 5–7].
The current UK RA clinical guidelines recommend a
minimum dialyser urea clearance of.66% [12], in keep-
ing with many other international guideline recommen-
dations [13, 14]. It is reassuring that the proportion of
UK haemodialysis patients achieving this target URR
has increased from 2002, with now more than 88% of
the prevalent HD population achieving the guideline
target in 2015. This improvement in delivered dialysis
dose reﬂects improvements in not only clinical practice
and haemodialysis technology [15], but also enhanced
coverage and quality of the data collected by the UKRR
from renal centres over time.
Observational studies and post hoc analyses of the
HEMO study and observational studies have suggested
that women may beneﬁt from a greater dialyser urea
clearance than men [16, 17]. Neither UK RA nor other
clinical guidelines advocate different targets based on
gender [12]. Typically, women are smaller than men
and have lower dietary intakes, as such serum urea con-
centrations are lower, and as such less dialyser urea clear-
ance is required to achieve a similar URR compared to a
larger male. However, this effect of an over estimation of
delivered dialysis dose also applies to Kt/V urea [18, 19].
Although women may be smaller and have a different
body composition to men, they have a relatively greater
resting energy expenditure [10, 20], and as such it has
been suggested to adjust dialyser urea clearance for
body surface area rather than body water [21]. It is there-
fore reassuring that in the UK, the median sessional URR
was higher for women than men.
Previous studies have not investigated whether urea
dialyser clearance targets should be adjusted for age.
Over the last ﬁfteen years the average age of patients
dialysing in UK dialysis centres has steadily increased.
It was found that the sessional urea clearance delivered
to older prevalent patients was greater than that for
younger patients. Body composition changes with age
as muscle mass declines [22], and as such both resting
and total energy expenditure tend to decline with age
along with dietary intake [10]. As such it would be
expected that younger more active patients would
require greater clearances than older patients. Although
the results paradoxically suggest lower clearances
delivered to younger patients, these results may be con-
founded by higher pre-dialysis serum urea values in the
younger patients, and differences in body composition
[23, 24].
A difference between centres in achieving the URR
sessional urea clearance target of .65% for prevalent
HD patients, ranging from 73.5–97.3% of patients was
noted. This is most likely to reﬂect genuine differences
in patient mix between centres and centre level clinical
practice. As such, understanding differences in patient
populations (inner city compared to rural, ethnicity, age,
comorbidity and centre practices including incremental
approaches to dialysis [25], vascular access, and use of
high ﬂux dialysis and haemodiaﬁltration [26]) are impor-
tant in understanding variation between centres.
Reimbursement for haemodialysis changed some years
ago to payment per session to encourage the delivery of
more frequent dialysis compared to the thrice weekly
paradigm [27]. Despite ﬁnancial encouragement to
provide more frequent dialysis, most UK centres con-
tinue to provide thrice weekly dialysis to the clear
majority of patients, although three of 71 (4.2%) centres
now provide more frequent dialysis schedules to more
than 10% of their prevalent HD patients, and nine centres
(12.7%) treat .5% of patients with more frequent
dialysis.
Interestingly, sessional URR was not signiﬁcantly
lower for more frequent dialysis compared to thrice
weekly dialysis. However, as only 2.2% of patients dia-
lysed more frequently it is unclear as to whether UK
dialysis centres alter dialysis times when dialysing
patients more frequently [28]. On the other hand,
between 0–14.3% patients in different dialysis centres
dialyse less than thrice weekly. Not all UK dialysis centres
measure residual renal function on a regular basis, and
the question arises as to whether this difference in
practice reﬂects differences in centre practices in terms
of measuring residual renal function and adding this
clearance to dialyser clearance [29].
The great majority of prevalent patients dialysed
between 4–5 hours, with 25.2% dialysing for shorter
times (,4 hours) and 0.6% dialysing for longer (.5
hours). Again, centre practices showed marked differ-
ences, with a wide range (0.8–88.0%) of patients dialysing
for less than four hours. Twenty-seven of the 55 centres
that provided data on time dialysed (49.1%), dialysed
.20% of patients for ,4 hours. The median URR was
similar whether patients dialysed for four hours or
more, or less than four hours, suggesting potential differ-
ences in centre practices in terms of blood pump speeds,
dialysate ﬂow rates and dialyser surface area. However
the differences in centre practices, in terms of shorter
dialysis session times and reduced frequency of dialysis
sessions, may additionally reﬂect some centres taking
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into account residual renal function, centres reducing the
amount of dialysis delivered to the elderly, but equally
may also be due to the limitation of the provision of
haemodialysis services, and these fundamental differ-
ences in centre practices require further investigation.
Most patients initiating HD have residual renal func-
tion, and as such some centres practice an incremental
approach to patients starting HD [30]. Sessional URR
increased with dialysis vintage in the incident patient
group, with the median URR ranging from 57–75%
between centres during the ﬁrst three months of dialysis,
which then increased to 69–80% after 12 months,
suggesting that most UK centres practised some form
of incremental dialysis, increasing dialysis session clear-
ance as residual renal function declined. Observational
studies have reported that preservation of residual renal
function is associated with improved survival [31],
however maintaining patients overhydrated on the basis
that this may preserve residual renal function does not
appear to sustain residual renal function [32], and indeed
may potentially increase cardiovascular mortality. As
most of the UK centres do not regularly measure residual
renal function, the authors are unable to comment on
differences in centre practices to initiating dialysis and
outcomes.
How much individualisation of dialysis prescription
based on residual renal function is practiced across UK
renal centres remains to be determined. More impor-
tantly, studies are required to determine whether preser-
vation of residual renal function improves patient
survival. Similarly, there is a need to establish whether
centre dialysis practices affect loss of residual renal func-
tion. Incompleteness of data returns by all centres,
including dialysis session information and other impor-
tant factors limits the interpretation of the data.
Although there is debate as to the relative toxicity of
urea, and how representative urea clearance is of other
azotaemic toxin clearances [8], dialyser urea clearance
remains the standard for dialysis dosing. Other factors
need to be considered, as the dialysis prescription should
also include volume control, sodium and divalent cation
balance and correction of metabolic acidosis. As such,
using sessional dialyser urea clearance dose based simply
on urea clearance has been criticised by some [17, 18],
arguing that patient survival can be improved by longer
sessional times [33, 34] and that clearance of ‘middle
molecules’ have an important impact [35, 36]. However,
no consensus has yet emerged on alternative markers of
HD adequacy [37]. The UKRR has historically reported
URR, predominantly for logistical reasons with the
URR being the easiest measure to calculate, and the
measure of dialysis adequacy that is most complete
when returned to the UKRR. However, limitations of
the URR must be recognised.
The new UKRR dataset, distributed to renal centres,
should help contribute to further improvements in both
URR data capture, as well as Kt/V reporting in addition
to data on dialysis prescription practice.
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